EU approves Teva bid for Allergan's generics with conditions
March 10, 2016 at 09:01 AM EST
BRUSSELS (Reuters) - The European Commission on Thursday approved Teva Pharmaceutical Industries' $40.5 billion acquisition of the generics activities of Allergan conditional on a number of divestments, notably Allergan businesses in Britain and Ireland.
